Table 4:

Comparison of Schirmer test score by novel autoantibody status at baseline in the Penn Sjogren’s International Clinical Collaborative Alliance (SICCA) Study Participants without Sjogren’s Syndrome (n=129)

Novel antibody	Novel Antibody Absence		Novel Antibody Presence
	n	Mean (SD)	n	Mean (SD)	P-value
Salivary protein 1 (SP-1)
IgG	123	10.7 (8.8)	6	8.7 (6.5)	0.57
IgA	125	10.6 (8.8)	4	11.5 (7.1)	0.84
IgM	123	10.8 (8.9)	6	7.7 (3.8)	0.40
Any	113	10.9 (9.1)	16	9.0 (5.6)	0.43
Carbonic anhydrase 6 (CA-6)
IgG	121	10.6 (8.9)	8	11.3 (6.6)	0.84
IgA	120	11.1 (8.8)	9	3.5 (2.0)	0.02
IgM	117	10.6 (8.8)	12	11.2 (8.7)	0.82
Any	103	11.0 (8.9)	26	9.0 (7.8)	0.31
Parotid specific protein (PSP)
IgG	123	10.5 (8.7)	6	12.8 (10.2)	0.53
IgA	115	10.6 (8.7)	14	10.8 (9.5)	0.94
IgM	118	10.7 (8.8)	11	9.9 (7.9)	0.78
Any	102	10.5 (8.6)	27	11.2 (9.2)	0.71
Any novel antibody	83	10.6 (8.6)	46	10.7 (9.0)	0.92
Number of novel antibodies positive
0	83	10.6 (8.6)
1	24	13.1 (11.1)
2–3*	22	8.2 (5.1)
	P=0.17 (any difference) P=0.51 for linear trend test

^*Only 1 patient had a value of 3.